期刊
BLOOD
卷 140, 期 13, 页码 1507-1521出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2021014495
关键词
-
类别
资金
- National Institutes of Health (National Institute of General Medical Sciences) [P50GM115279]
- National Institutes of Health (National Cancer Institute) [P30CA21765, U01CA264610]
- American Lebanese Syrian Associated Charities
T-cell immunity plays a pivotal role in maintaining long-term remission of acute lymphoblastic leukemia (ALL) and the interplay between host immunity and drug resistance can be harnessed to improve chemotherapy outcomes for ALL.
Although acute lymphoblastic leukemia (ALL) is highly responsive to chemotherapy, it is unknown how or which host immune factors influence the long-term remission of this cancer. To this end, we systematically evaluated the effects of T-cell immunity on Ph+ ALL therapy outcomes. Using a murine Arf-/- BCR-ABL1 B-cell ALL model, we showed that loss of T cells in the host drastically increased leukemia relapse after dasatinib or cytotoxic chemotherapy. Although ABL1 mutations emerged early during dasatinib treatment in both immunocompetent and immunocompromised hosts, T-cell immunity was essential for suppressing the outgrowth of drug-resistant leukemia. Bulk and single-cell transcriptome profiling of T cells during therapy pointed to the activation of type 1 immunity-related cytokine signaling being linked to long-term leukemia remission in mice. Consistent with these observations, interferon g and interleukin 12 directly modulated dasatinib antileukemia efficacy in vivo. Finally, we evaluated peripheral blood immune cell composition in 102 children with ALL during chemotherapy and observed a significant association of T-cell abundance with treatment outcomes. Together, these results suggest that T-cell immunity plays pivotal roles in maintaining long-term remission of ALL, highlighting that the interplay between host immunity and drug resistance can be harnessed to improve ALL chemotherapy outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据